|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 47/60 | (2017.01) |
| A61K 31/505 | (2006.01) | ||
| A61K 38/22 | (2006.01) | ||
| A61K 38/27 | (2006.01) | ||
| A61P 19/08 | (2006.01) |
| (11) | Number of the document | 3518930 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17781429.0 |
| Date of filing the European patent application | 2017-09-28 | |
| (97) | Date of publication of the European application | 2019-08-07 |
| (45) | Date of publication and mention of the grant of the patent | 2023-03-08 |
| (46) | Date of publication of the claims translation | 2023-05-10 |
| (86) | Number | PCT/EP2017/074596 |
| Date | 2017-09-28 |
| (87) | Number | WO 2018/060314 |
| Date | 2018-04-05 |
| (30) | Number | Date | Country code |
| 16191456 | 2016-09-29 | EP |
| (72) |
HOLTEN-ANDERSEN, Lars , DK
MILLER BREINHOLT, Vibeke , DK
SPROGØE, Kennett , DK
|
| (73) |
Ascendis Pharma Growth Disorders A/S ,
Tuborg Boulevard 12, 2900 Hellerup,
DK
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kompleksinė terapija su kontroliuojamo išskyrimo CNP agonistais |
| COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS |
| Payment date | Validity (years) | Amount | |
| 2025-09-11 | 9 | 208.00 EUR |
| 2026-09-28 |